1 | arms | 8,014 |
2 | sexes | 943 |
3 | sides | 766 |
4 | genders | 544 |
5 | hemispheres | 118 |
6 | tonometers | 27 |
7 | groups.the | 25 |
8 | mbrs | 12 |
9 | armpits | 6 |
10 | avf2107g | 6 |
11 | groups.two | 5 |
12 | hiphos | 4 |
13 | polities | 4 |
14 | tbdcl1 | 4 |
15 | α-chains | 4 |
16 | -before | 3 |
17 | 2am | 3 |
18 | alloforms | 3 |
19 | arms.the | 3 |
20 | bia-2093-204 | 3 |
21 | blastodiscs | 3 |
22 | glucuronidations | 3 |
23 | groups.there | 3 |
24 | nbcas | 3 |
25 | post-and | 3 |
26 | pyl-stb | 3 |
27 | qus-devices | 3 |
28 | rr-qt | 3 |
29 | scalps | 3 |
30 | sipm | 3 |
31 | smeddss | 3 |
32 | triumvirates | 3 |
33 | 1995-97 | 2 |
34 | adrenocorticotrophic-hormone | 2 |
35 | cd27- | 2 |
36 | emads | 2 |
37 | failure/resistance | 2 |
38 | fluoxetine- | 2 |
39 | forelegs | 2 |
40 | goups | 2 |
41 | groups.one | 2 |
42 | lrs114688 | 2 |
43 | mpdss | 2 |
44 | pathomorphologies | 2 |
45 | per-formed | 2 |
46 | rc/cmg | 2 |
47 | reactor-status | 2 |
48 | regimens/strategies | 2 |
49 | tau-pvs | 2 |
50 | transphosphatidylation | 2 |
51 | +yhr | 1 |
52 | -loud | 1 |
53 | 0218 | 1 |
54 | 1-epimers | 1 |
55 | 1-t1 | 1 |
56 | 13.9±7.0 | 1 |
57 | 13/20°c | 1 |
58 | 13181a | 1 |
59 | 17β-estradiol-2,3-quinone | 1 |
60 | 2-t2 | 1 |
61 | 26981-22981 | 1 |
62 | 47/942 | 1 |
63 | 5-fu+cddp | 1 |
64 | 6-beta- | 1 |
65 | 64-msct | 1 |
66 | a4001078 | 1 |
67 | administration.mifepristone | 1 |
68 | anhydrohexitol | 1 |
69 | antisecretors | 1 |
70 | arterial-line | 1 |
71 | aspartat-amino-transaminase | 1 |
72 | atx-groups | 1 |
73 | avian-type | 1 |
74 | boronophenylalanine | 1 |
75 | bos-i | 1 |
76 | c-ho | 1 |
77 | c3h8no3 | 1 |
78 | ca-ionophore | 1 |
79 | casccades | 1 |
80 | cba/cah | 1 |
81 | centres/countries | 1 |
82 | chqs-the | 1 |
83 | cruciates | 1 |
84 | d/prednisone | 1 |
85 | dehydrothermal | 1 |
86 | dichlorphenamide | 1 |
87 | difference/sd | 1 |
88 | dmba- | 1 |
89 | dorzolamide/brimonidine/timolol | 1 |
90 | ducts/alveoli | 1 |
91 | effect=2.56 | 1 |
92 | engagement.methods | 1 |
93 | eqas | 1 |
94 | ethyleneglycol-bis | 1 |
95 | exp. | 1 |
96 | eyes.subjects | 1 |
97 | follitropins | 1 |
98 | galactose-alpha | 1 |
99 | gcc-groups | 1 |
100 | globotriose-lipopolysaccharide | 1 |
101 | gonaducts | 1 |
102 | group-tg | 1 |
103 | groups-fluoxetine | 1 |
104 | groups-specific | 1 |
105 | groups.while | 1 |
106 | gzd-vf2 | 1 |
107 | hemi-arches | 1 |
108 | history/outcomes | 1 |
109 | hpv-007 | 1 |
110 | hspa820 | 1 |
111 | ibandronate- | 1 |
112 | idiomorphs | 1 |
113 | inbreds | 1 |
114 | incision/tur | 1 |
115 | inositides | 1 |
116 | keliximab | 1 |
117 | late-stage- | 1 |
118 | level-i-i | 1 |
119 | low-lipase | 1 |
120 | mgts | 1 |
121 | mois | 1 |
122 | mrjps | 1 |
123 | nano-forms | 1 |
124 | negative/antagonistic | 1 |
125 | nitro/methoxy | 1 |
126 | non-separated | 1 |
127 | nos-inhibitors | 1 |
128 | one-to- | 1 |
129 | orlistat-and | 1 |
130 | papp-a-multiples | 1 |
131 | pariners | 1 |
132 | partage | 1 |
133 | partner/informant | 1 |
134 | period-hba1c1 | 1 |
135 | pgf2α=44.5 | 1 |
136 | pgf2α=95.9 | 1 |
137 | phenylacetaldehyde/creati | 1 |
138 | phosphodiesterase-4b | 1 |
139 | ploidies | 1 |
140 | points-in-time | 1 |
141 | postplanning | 1 |
142 | pre-dca | 1 |
143 | prices/day | 1 |
144 | proteingrams | 1 |
145 | rr1.15 | 1 |
146 | rs=0.593 | 1 |
147 | sc-51322 | 1 |
148 | scale-sleep | 1 |
149 | scopists | 1 |
150 | sct- | 1 |
151 | sec-ftir | 1 |
152 | use-regimens | 1 |
153 | use/dosage | 1 |
154 | verdazyls | 1 |
155 | vsa/cd31 | 1 |
156 | williopsis | 1 |
157 | year.comparator | 1 |
158 | δurec | 1 |
1 | +yhr | 1 |
2 | -before | 3 |
3 | -loud | 1 |
4 | 0218 | 1 |
5 | 1-epimers | 1 |
6 | 1-t1 | 1 |
7 | 13.9±7.0 | 1 |
8 | 13/20°c | 1 |
9 | 13181a | 1 |
10 | 17β-estradiol-2,3-quinone | 1 |
11 | 1995-97 | 2 |
12 | 2-t2 | 1 |
13 | 26981-22981 | 1 |
14 | 2am | 3 |
15 | 47/942 | 1 |
16 | 5-fu+cddp | 1 |
17 | 6-beta- | 1 |
18 | 64-msct | 1 |
19 | a4001078 | 1 |
20 | administration.mifepristone | 1 |
21 | adrenocorticotrophic-hormone | 2 |
22 | alloforms | 3 |
23 | anhydrohexitol | 1 |
24 | antisecretors | 1 |
25 | armpits | 6 |
26 | arms | 8,014 |
27 | arms.the | 3 |
28 | arterial-line | 1 |
29 | aspartat-amino-transaminase | 1 |
30 | atx-groups | 1 |
31 | avf2107g | 6 |
32 | avian-type | 1 |
33 | bia-2093-204 | 3 |
34 | blastodiscs | 3 |
35 | boronophenylalanine | 1 |
36 | bos-i | 1 |
37 | c-ho | 1 |
38 | c3h8no3 | 1 |
39 | ca-ionophore | 1 |
40 | casccades | 1 |
41 | cba/cah | 1 |
42 | cd27- | 2 |
43 | centres/countries | 1 |
44 | chqs-the | 1 |
45 | cruciates | 1 |
46 | d/prednisone | 1 |
47 | dehydrothermal | 1 |
48 | dichlorphenamide | 1 |
49 | difference/sd | 1 |
50 | dmba- | 1 |
51 | dorzolamide/brimonidine/timolol | 1 |
52 | ducts/alveoli | 1 |
53 | effect=2.56 | 1 |
54 | emads | 2 |
55 | engagement.methods | 1 |
56 | eqas | 1 |
57 | ethyleneglycol-bis | 1 |
58 | exp. | 1 |
59 | eyes.subjects | 1 |
60 | failure/resistance | 2 |
61 | fluoxetine- | 2 |
62 | follitropins | 1 |
63 | forelegs | 2 |
64 | galactose-alpha | 1 |
65 | gcc-groups | 1 |
66 | genders | 544 |
67 | globotriose-lipopolysaccharide | 1 |
68 | glucuronidations | 3 |
69 | gonaducts | 1 |
70 | goups | 2 |
71 | group-tg | 1 |
72 | groups-fluoxetine | 1 |
73 | groups-specific | 1 |
74 | groups.one | 2 |
75 | groups.the | 25 |
76 | groups.there | 3 |
77 | groups.two | 5 |
78 | groups.while | 1 |
79 | gzd-vf2 | 1 |
80 | hemi-arches | 1 |
81 | hemispheres | 118 |
82 | hiphos | 4 |
83 | history/outcomes | 1 |
84 | hpv-007 | 1 |
85 | hspa820 | 1 |
86 | ibandronate- | 1 |
87 | idiomorphs | 1 |
88 | inbreds | 1 |
89 | incision/tur | 1 |
90 | inositides | 1 |
91 | keliximab | 1 |
92 | late-stage- | 1 |
93 | level-i-i | 1 |
94 | low-lipase | 1 |
95 | lrs114688 | 2 |
96 | mbrs | 12 |
97 | mgts | 1 |
98 | mois | 1 |
99 | mpdss | 2 |
100 | mrjps | 1 |
101 | nano-forms | 1 |
102 | nbcas | 3 |
103 | negative/antagonistic | 1 |
104 | nitro/methoxy | 1 |
105 | non-separated | 1 |
106 | nos-inhibitors | 1 |
107 | one-to- | 1 |
108 | orlistat-and | 1 |
109 | papp-a-multiples | 1 |
110 | pariners | 1 |
111 | partage | 1 |
112 | partner/informant | 1 |
113 | pathomorphologies | 2 |
114 | per-formed | 2 |
115 | period-hba1c1 | 1 |
116 | pgf2α=44.5 | 1 |
117 | pgf2α=95.9 | 1 |
118 | phenylacetaldehyde/creati | 1 |
119 | phosphodiesterase-4b | 1 |
120 | ploidies | 1 |
121 | points-in-time | 1 |
122 | polities | 4 |
123 | post-and | 3 |
124 | postplanning | 1 |
125 | pre-dca | 1 |
126 | prices/day | 1 |
127 | proteingrams | 1 |
128 | pyl-stb | 3 |
129 | qus-devices | 3 |
130 | rc/cmg | 2 |
131 | reactor-status | 2 |
132 | regimens/strategies | 2 |
133 | rr-qt | 3 |
134 | rr1.15 | 1 |
135 | rs=0.593 | 1 |
136 | sc-51322 | 1 |
137 | scale-sleep | 1 |
138 | scalps | 3 |
139 | scopists | 1 |
140 | sct- | 1 |
141 | sec-ftir | 1 |
142 | sexes | 943 |
143 | sides | 766 |
144 | sipm | 3 |
145 | smeddss | 3 |
146 | tau-pvs | 2 |
147 | tbdcl1 | 4 |
148 | tonometers | 27 |
149 | transphosphatidylation | 2 |
150 | triumvirates | 3 |
151 | use-regimens | 1 |
152 | use/dosage | 1 |
153 | verdazyls | 1 |
154 | vsa/cd31 | 1 |
155 | williopsis | 1 |
156 | year.comparator | 1 |
157 | α-chains | 4 |
158 | δurec | 1 |
1 | cd27- | 2 |
2 | dmba- | 1 |
3 | 6-beta- | 1 |
4 | late-stage- | 1 |
5 | fluoxetine- | 2 |
6 | ibandronate- | 1 |
7 | one-to- | 1 |
8 | sct- | 1 |
9 | exp. | 1 |
10 | 13.9±7.0 | 1 |
11 | hspa820 | 1 |
12 | vsa/cd31 | 1 |
13 | 26981-22981 | 1 |
14 | period-hba1c1 | 1 |
15 | tbdcl1 | 4 |
16 | 1-t1 | 1 |
17 | sc-51322 | 1 |
18 | 47/942 | 1 |
19 | gzd-vf2 | 1 |
20 | 2-t2 | 1 |
21 | rs=0.593 | 1 |
22 | c3h8no3 | 1 |
23 | bia-2093-204 | 3 |
24 | pgf2α=44.5 | 1 |
25 | rr1.15 | 1 |
26 | effect=2.56 | 1 |
27 | hpv-007 | 1 |
28 | 1995-97 | 2 |
29 | 0218 | 1 |
30 | a4001078 | 1 |
31 | lrs114688 | 2 |
32 | pgf2α=95.9 | 1 |
33 | 13181a | 1 |
34 | pre-dca | 1 |
35 | galactose-alpha | 1 |
36 | phosphodiesterase-4b | 1 |
37 | keliximab | 1 |
38 | pyl-stb | 3 |
39 | δurec | 1 |
40 | groups-specific | 1 |
41 | negative/antagonistic | 1 |
42 | 13/20°c | 1 |
43 | per-formed | 2 |
44 | non-separated | 1 |
45 | orlistat-and | 1 |
46 | post-and | 3 |
47 | difference/sd | 1 |
48 | -loud | 1 |
49 | failure/resistance | 2 |
50 | dichlorphenamide | 1 |
51 | globotriose-lipopolysaccharide | 1 |
52 | use/dosage | 1 |
53 | partage | 1 |
54 | chqs-the | 1 |
55 | arms.the | 3 |
56 | groups.the | 25 |
57 | groups.while | 1 |
58 | points-in-time | 1 |
59 | arterial-line | 1 |
60 | boronophenylalanine | 1 |
61 | groups-fluoxetine | 1 |
62 | groups.one | 2 |
63 | adrenocorticotrophic-hormone | 2 |
64 | 17β-estradiol-2,3-quinone | 1 |
65 | d/prednisone | 1 |
66 | administration.mifepristone | 1 |
67 | avian-type | 1 |
68 | groups.there | 3 |
69 | -before | 3 |
70 | ca-ionophore | 1 |
71 | aspartat-amino-transaminase | 1 |
72 | low-lipase | 1 |
73 | avf2107g | 6 |
74 | rc/cmg | 2 |
75 | postplanning | 1 |
76 | group-tg | 1 |
77 | cba/cah | 1 |
78 | level-i-i | 1 |
79 | bos-i | 1 |
80 | ducts/alveoli | 1 |
81 | phenylacetaldehyde/creati | 1 |
82 | dehydrothermal | 1 |
83 | dorzolamide/brimonidine/timolol | 1 |
84 | anhydrohexitol | 1 |
85 | 2am | 3 |
86 | sipm | 3 |
87 | transphosphatidylation | 2 |
88 | c-ho | 1 |
89 | groups.two | 5 |
90 | 5-fu+cddp | 1 |
91 | scale-sleep | 1 |
92 | +yhr | 1 |
93 | sec-ftir | 1 |
94 | year.comparator | 1 |
95 | incision/tur | 1 |
96 | nbcas | 3 |
97 | eqas | 1 |
98 | blastodiscs | 3 |
99 | emads | 2 |
100 | inbreds | 1 |
101 | engagement.methods | 1 |
102 | qus-devices | 3 |
103 | casccades | 1 |
104 | sides | 766 |
105 | inositides | 1 |
106 | hemi-arches | 1 |
107 | ploidies | 1 |
108 | regimens/strategies | 2 |
109 | pathomorphologies | 2 |
110 | centres/countries | 1 |
111 | polities | 4 |
112 | papp-a-multiples | 1 |
113 | history/outcomes | 1 |
114 | hemispheres | 118 |
115 | cruciates | 1 |
116 | triumvirates | 3 |
117 | sexes | 943 |
118 | forelegs | 2 |
119 | idiomorphs | 1 |
120 | ethyleneglycol-bis | 1 |
121 | mois | 1 |
122 | williopsis | 1 |
123 | verdazyls | 1 |
124 | proteingrams | 1 |
125 | arms | 8,014 |
126 | nano-forms | 1 |
127 | alloforms | 3 |
128 | use-regimens | 1 |
129 | α-chains | 4 |
130 | follitropins | 1 |
131 | glucuronidations | 3 |
132 | hiphos | 4 |
133 | mrjps | 1 |
134 | scalps | 3 |
135 | goups | 2 |
136 | gcc-groups | 1 |
137 | atx-groups | 1 |
138 | mbrs | 12 |
139 | genders | 544 |
140 | 1-epimers | 1 |
141 | pariners | 1 |
142 | tonometers | 27 |
143 | antisecretors | 1 |
144 | nos-inhibitors | 1 |
145 | smeddss | 3 |
146 | mpdss | 2 |
147 | eyes.subjects | 1 |
148 | gonaducts | 1 |
149 | mgts | 1 |
150 | armpits | 6 |
151 | scopists | 1 |
152 | reactor-status | 2 |
153 | tau-pvs | 2 |
154 | 64-msct | 1 |
155 | partner/informant | 1 |
156 | rr-qt | 3 |
157 | prices/day | 1 |
158 | nitro/methoxy | 1 |